Welcome to our dedicated page for Elevance Health SEC filings (Ticker: ELV), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Elevance Health, Inc. (NYSE: ELV) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Elevance Health operates in the direct health and medical insurance carriers industry and uses its SEC reports to present information on financial performance, capital structure, governance, and material events affecting its health benefits and Carelon segments.
Among the most important documents for ELV are its annual reports on Form 10-K and quarterly reports on Form 10-Q. These filings typically include detailed discussions of segment results for Health Benefits and Carelon, membership metrics across commercial, Medicare, Medicaid, and Federal Employee Program lines, risk factors, and management’s analysis of trends in benefit expense ratios, operating expenses, and cash flows. They also describe Elevance Health’s role as a licensee of Blue Cross Blue Shield plans in multiple states and its activities in pharmacy and healthcare services through Carelon.
Elevance Health also files current reports on Form 8-K to disclose specific material events. Recent 8-Ks have covered quarterly earnings releases, reaffirmation of earnings guidance and benefit expense ratio expectations, the election of independent directors to the board and their committee assignments, and a multi-tranche notes offering with maturities extending to 2055. These filings provide insight into governance practices, capital markets activity, and management’s public communications with investors.
Investors interested in executive and board matters can review proxy-related filings and 8-K disclosures regarding director appointments and compensation programs for non-employee directors. Those analyzing Elevance Health’s capital structure can examine registration statements and debt-related exhibits referenced in 8-K filings, which describe terms of senior notes, redemption provisions, and events of default.
On Stock Titan, ELV filings are updated in near real time as they appear in the SEC’s EDGAR system. AI-powered tools summarize lengthy documents such as 10-Ks and 10-Qs, highlight key metrics and risk discussions, and help users quickly locate information on topics like Medicare and Medicaid program exposure, pharmacy and services operations under Carelon, and guidance-related forward-looking statements. Users can also review Form 4 insider transaction reports when available to monitor trading activity by Elevance Health directors and officers.
By using this filings page, investors and researchers can navigate Elevance Health’s regulatory history more efficiently, compare disclosures across reporting periods, and better understand how the company presents its health benefits and services business to regulators and the market.
Susan D. DeVore, a director of Elevance Health, reported purchases of common stock totaling 1,200 shares on 08/19/2025 at a weighted average price of $312.15 per share. After these purchases she beneficially owned 3,502 shares directly. The filing specifies the purchases were executed in multiple trades at prices between $312.06 and $312.19, and the weighted average price is disclosed. The Form 4 was signed by an attorney-in-fact for the reporting person.